You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Marginal Zone Lymphoma (MZL)

Showing 1 - 25 of 6,503
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Marginal Zone Lymphoma Trial in Tianjin (Obinutuzumab, lenalidomide)

Recruiting
  • Marginal Zone Lymphoma
  • Obinutuzumab, lenalidomide
  • Tianjin, Tian, China
    Institute of Hematology & Blood Diseases Hospital
Apr 27, 2023

Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL) Trial (parsaclisib, rituximab, obinutuzumab)

Withdrawn
  • Follicular Lymphoma ( FL)
  • Marginal Zone Lymphoma (MZL)
  • (no location specified)
Jul 14, 2022

Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL) Trial in Chiang Mai (Odronextamab, Lenalidomide,

Recruiting
  • Relapsed/Refractory Follicular Lymphoma
  • Marginal Zone Lymphoma (MZL)
  • Chiang Mai, Thailand
    Chiang Mai University
Nov 20, 2023

OR Regimen Refractory Marginal Zone Lymphoma Trial (obrutinib, rituximab)

Not yet recruiting
  • OR Regimen Refractory Marginal Zone Lymphoma
  • obrutinib, rituximab
  • (no location specified)
Nov 12, 2023

Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial (Routine care as per

Not yet recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +5 more
  • Routine care as per site standard.
  • (no location specified)
Sep 15, 2023

Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in Beijing

Recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • +6 more
  • Beijing, China
    Beijing Cancer Hospital
Feb 6, 2023

Revlimid® Capsules General Drug Use-results Surveillance

Recruiting
  • Lymphoma Nonhodgkin
    • Japan, Japan
      Local Institution
    Jun 22, 2022

    Marginal Zone Lymphoma Trial in Austria, Italy, Switzerland (Tafasitamab, Acalabrutinib)

    Recruiting
    • Marginal Zone Lymphoma
    • Wien, Austria
    • +9 more
    Jul 13, 2022

    Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL) Trial in Manchester,

    Recruiting
    • Chronic Lymphocytic Leukemia (CLL)
    • +7 more
    • Manchester, United Kingdom
    • +2 more
    Aug 11, 2022

    Follicular Lymphoma and Marginal Zone Lymphoma Trial in Beijing (Recombinant Humanized Monoclonal Antibody MIL62 Injection,

    Recruiting
    • Follicular Lymphoma and Marginal Zone Lymphoma
    • Recombinant Humanized Monoclonal Antibody MIL62 Injection
    • Lenalidomide
    • Beijing, China
      Chinese Academy of Medical Sciences and Peking Union Medical Col
    Jun 15, 2021

    Marginal Zone Lymphoma, Follicular Lymphoma, DLBCL Trial in China (Zanubrutinib, Rituximab)

    Completed
    Has Results
    • Marginal Zone Lymphoma
    • +2 more
    • Harbin, Heilongjiang, China
    • +3 more
    Oct 26, 2021

    Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL) Trial in United States (voruciclib

    Recruiting
    • Follicular Lymphoma (FL)
    • +6 more
    • voruciclib monotherapy
    • voruciclib and venetoclax
    • Duarte, California
    • +10 more
    Aug 10, 2022

    Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM) Trial in United States

    Recruiting
    • Chronic Lymphocytic Leukemia (CLL)
    • +6 more
    • Duarte, California
    • +10 more
    Jul 14, 2022

    Relapsed/Refractory B-cell Lymphomas, Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in United States

    Recruiting
    • Relapsed/Refractory B-cell Lymphomas
    • +11 more
    • CLBR001 and SWI019
    • Duarte, California
    • +7 more
    Jul 26, 2022

    Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma Trial in Boston (Obinutuzumab, Glofitamab)

    Not yet recruiting
    • Follicular Lymphoma
    • +2 more
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    Mar 13, 2023

    Marginal Zone Lymphoma Trial in Germany (Obinutuzumab)

    Active, not recruiting
    • Marginal Zone Lymphoma
    • Bochum, Germany
    • +15 more
    Nov 4, 2022

    Marginal Zone Lymphoma Trial (Mosunetuzumab + Lenalidomide, - Rituximab + Lenalidomide (28-days cycles, - Rituximab +

    Not yet recruiting
    • Marginal Zone Lymphoma
    • Mosunetuzumab + Lenalidomide
    • +3 more
    • (no location specified)
    Aug 16, 2023

    Marginal Zone Lymphoma Trial ([68Ga]Ga-PentixaFor, [18F]Fluorodeoxyglucose)

    Not yet recruiting
    • Marginal Zone Lymphoma
    • (no location specified)
    Nov 6, 2023

    Indolent Non-hodgkin Lymphoma Trial in Shanghai (IBI376)

    Active, not recruiting
    • Indolent Non-hodgkin Lymphoma
    • Shanghai, China
      Ruijin hospital, school of medicine, Shanghai jiao tong universi
    Oct 3, 2022

    Lymphoma Trial (Ultra Low Dose 4 Gy Radiation)

    Not yet recruiting
    • Lymphoma
    • Ultra Low Dose 4 Gy Radiation
    • (no location specified)
    Jun 30, 2023

    Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

    Recruiting
    • Follicular Lymphoma
    • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 20, 2023

    Marginal Zone Lymphoma, Follicular Lymphoma Trial in Aurora (Ublituximab, Umbralisib)

    Suspended
    • Marginal Zone Lymphoma
    • Follicular Lymphoma
    • Aurora, Colorado
      University of Colorado Hospital
    Feb 22, 2022

    Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in

    Suspended
    • Recurrent B-Cell Non-Hodgkin Lymphoma
    • +7 more
    • Philadelphia, Pennsylvania
      Sidney Kimmel Cancer Center at Thomas Jefferson University
    Jan 20, 2023

    Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma Trial in Worldwide (Ibrutinib, Rituximab)

    Recruiting
    • Marginal Zone Lymphoma
    • +2 more
    • Yvoir, Belgium
    • +36 more
    Nov 4, 2022

    Marginal Zone Lymphoma Trial in Austria, Germany (Copanlisib, Rituximab)

    Recruiting
    • Marginal Zone Lymphoma
    • Wien, Austria
    • +19 more
    Mar 14, 2022